ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
17 hedge funds and large institutions have $1.04M invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
52% more capital invested
Capital invested by funds: $684K → $1.04M (+$355K)
6% more funds holding
Funds holding: 16 → 17 (+1)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$50.1K |
| 2 |
BlackRock
New York
|
+$1.75K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$337 |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$248 |
| 5 |
Morgan Stanley
New York
|
+$144 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$52.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.1K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$65 |
IMUC Hedge Fund Activity: Q1 2017 in Review
17 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q1 2017, worth a combined $1.04M — up 52% from $684K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IMUC positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $50.1K. The largest seller was Sabby Management, cutting an estimated $52.8K.
- 17 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q1 2017, up from 16 in Q4 2016.
- Funds reported $1.04M of ImmunoCellular Therapeutics, Ltd. stock for Q1 2017, up 52% quarter-over-quarter.
- 3 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q1 2017 and 1 closed out, a net change of +2 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q1 2017 was Renaissance Technologies, an estimated $50.1K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q1 2017 was Sabby Management, an estimated $52.8K sold.
Based on aggregated 13F filings for Q1 2017.